Felzartamab infusions for IgA nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called Felzartamab (given as an infusion) for people with IgA nephropathy (IgAN), a kidney disease. The goal is to see if it can reduce protein leaking into urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a kidney biopsy confirming IgA nephropathy (IgAN) within the past 10 years (or 2 years if you have type 2 diabetes).
- Your kidney function (eGFR) must be at least 30 mL/min/1.73 m² (or at least 20 in some cases).
- You must have significant protein in your urine (at least 1 gram per day) from a 24-hour urine collection.
- You need to be on a stable dose of blood pressure medicines (ACE inhibitors or ARBs) for at least 12 weeks before joining.
- You cannot have taken strong immune-suppressing drugs or steroids for IgAN in the last 4 months.
- You should not have other serious kidney diseases, active infections, or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zigakibart for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help reduce protein in the urine and protect kidney function.
This trial tests a new drug called cizutamig for people with IgA nephropathy who still have high protein in their urine despite trying other treatments. It aims to see if the drug can help protect kidney function.
This trial tests a drug called felzartamab to see if it can help people who have a type of kidney inflammation after a transplant, even without donor-specific antibodies. It might offer a new treatment option for those who are not getting better on their own.
This study tests whether felzartamab, given as an infusion, can help treat primary membranous nephropathy (a kidney disease causing protein in the urine and swelling). It may reduce protein loss and improve kidney function compared to standard care alone.
This trial tests a new drug called mezagitamab for adults with IgA nephropathy, a kidney condition. The study aims to see if this drug can help reduce protein in the urine and preserve kidney function. You may be eligible if your kidney function is above a certain level and your urine protein is high enough.
This trial tests a new medicine called FXS6837 for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help protect kidney function. Participants must have a recent kidney biopsy showing certain features and stable kidney function.
Hear when a new Immunoglobulin A Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.